Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasted to Post FY2028 Earnings of $2.35 Per Share

Zevra Therapeutics, Inc. (NASDAQ:ZVRAFree Report) – Analysts at Roth Capital dropped their FY2028 earnings estimates for Zevra Therapeutics in a report issued on Sunday, March 31st. Roth Capital analyst J. Aschoff now expects that the company will earn $2.35 per share for the year, down from their prior forecast of $2.50. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.38) per share.

ZVRA has been the topic of several other reports. William Blair reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, March 12th. Maxim Group increased their price target on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research report on Monday. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Zevra Therapeutics in a research report on Tuesday, March 5th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zevra Therapeutics presently has an average rating of “Buy” and a consensus target price of $19.50.

Check Out Our Latest Report on ZVRA

Zevra Therapeutics Stock Down 0.9 %

ZVRA opened at $5.12 on Tuesday. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.65. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $7.28. The company has a market capitalization of $185.27 million, a PE ratio of -3.97 and a beta of 1.81. The firm’s 50 day simple moving average is $6.14 and its two-hundred day simple moving average is $5.38.

Hedge Funds Weigh In On Zevra Therapeutics

A number of large investors have recently made changes to their positions in the company. Nantahala Capital Management LLC boosted its stake in shares of Zevra Therapeutics by 6.3% during the 4th quarter. Nantahala Capital Management LLC now owns 2,453,405 shares of the company’s stock worth $16,070,000 after purchasing an additional 145,189 shares during the period. Vanguard Group Inc. lifted its holdings in Zevra Therapeutics by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 1,645,140 shares of the company’s stock valued at $10,776,000 after buying an additional 32,639 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in Zevra Therapeutics by 1.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 683,431 shares of the company’s stock valued at $4,476,000 after buying an additional 9,062 shares in the last quarter. Retirement Planning Co of New England Inc. bought a new stake in Zevra Therapeutics during the 3rd quarter valued at about $1,674,000. Finally, Northern Trust Corp lifted its holdings in Zevra Therapeutics by 11.3% during the 4th quarter. Northern Trust Corp now owns 301,066 shares of the company’s stock valued at $1,972,000 after buying an additional 30,624 shares in the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Further Reading

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.